New antibody drug targets kidney damage in lupus patients
NCT ID NCT06064929
First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works in the body, while all participants continue their usual treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- felzartamab (a lab-made antibody given by IV)
- What this could lead to
- If it works, this could point toward a new treatment option for lupus nephritis that helps reduce kidney damage.
- What could go wrong
- This is a very early, small Phase 1b trial with only 14 people, so results may not apply to everyone. The main goal is safety, not yet proof of effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Accurate Clinical Research - Katy
Katy, Texas, 77449, United States
-
CEMIC
CABA, Buenos Aires F.D., C1431FWO, Argentina
-
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
Montreal, Quebec, H2X 3J4, Canada
-
ClinCept, LLC/River City Vascular Specialists LLC
Columbus, Georgia, 31904, United States
-
Clinica Priv Velez Sarsfield
Córdoba, Córdoba Province, X5016, Argentina
-
Georgia Nephrology - Lawrenceville
Lawrenceville, Georgia, 30046, United States
-
Hospital Britanico de Buenos Aires
Caba, Buenos Aires F.D., C1280AEB, Argentina
-
Joseph S. and Diane H. Steinberg Ambulatory Care Center
Brooklyn, New York, 11201, United States
-
Monash Health
Melbourne, Victoria, 3168, Australia
-
Precision Comprehensive Clinical Research Solutions - Grapevine
Grapevine, Texas, 76051, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Prolato Clinical Research Center
Houston, Texas, 77054, United States
-
R & H Clinical Research
Katy, Texas, 77450, United States
-
SUNY Downstate Medical Center
Brooklyn, New York, 11203, United States
-
St. Paul's Hospital
Vancouver, British Columbia, V6Z1Y6, Canada
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
The Ohio State University (OSU)
Columbus, Ohio, 43210, United States
-
University Health Network - Toronto General Division
Toronto, Ontario, MST258, Canada
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California, San Diego (UCSD)
La Jolla, California, 92037, United States
-
University of California, San Francisco (UCSF)
San Francisco, California, 94143, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Western Health
Saint Albans, Victoria, 3021, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a single infusion tame tough lupus?
- Can a smartphone app bridge the lupus care gap for women of color?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Cancer drug shows promise for lupus kidney disease